Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;3(12):e829-e831.
doi: 10.1016/S2665-9913(21)00321-0. Epub 2021 Oct 29.

IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19

Emanuel Della-Torre  1   2 , Elena Criscuolo  3 , Marco Lanzillotta  1   2 , Massimo Locatelli  4 , Nicola Clementi  1   3 , Nicasio Mancini  1   3 , Lorenzo Dagna  1   2 ; COVID-BioB study group
Affiliations

IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19

Emanuel Della-Torre et al. Lancet Rheumatol. 2021 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests. This study was supported by IRCCS San Raffaele Hospital Program Project COVID-19 funds. EC did the neutralisation experiments. NC, NM, and MLo contributed to the study design, analysed and interpreted the data, and critically discussed the manuscript. ED-T conceived the study, contributed to the study design, enrolled patients to biological therapy, analysed and interpreted the data, drafted the final version of the manuscript, and critically discussed the manuscript. MLa and LD contributed to the study design, enrolled patients to biological therapy, analysed and interpreted the data, critically discussed the manuscript. NM and LD contributed equally as last authors. Members of the COVID-BioB study group are listed in the appendix (p 4).

Figures

Figure
Figure
Features of anti-SARS-CoV-2 humoral response in patients treated with anti-IL-1 and anti-IL-6 therapies (A) Concentration of anti-RBD serum antibodies in patients treated with the local standard of care, anti-IL-6 (sarilumab or tocilizumab), and anti-IL-1 (anakinra). Horizontal lines represents medians of 10 measurements performed in triplicate. (B) In vitro anti-SARS-CoV-2 neutralising activity of sera from patients treated with the local standard of care, IL-1, and IL-6 blocking agents. Neutralising antibody activity was measured at baseline, at day 30, and at day 60. Results are reported as medians and 95% CI of 10 measurements performed in triplicate. RBD=receptor-binding domain.
See this image and copyright information in PMC

References

    1. De Giovanni M, Cutillo V, Giladi A, et al. Spatiotemporal regulation of type I interferon expression determines the antiviral polarization of CD4+ T cells. Nat Immunol. 2020;21:321–330. - PMC - PubMed
    1. Della-Torre E, Lanzillotta M, Campochiaro C, et al. Respiratory impairment predicts response to IL-1 and IL-6 blockade in COVID-19 patients with severe pneumonia and hyper-inflammation. Front Immunol. 2021;12 - PMC - PubMed
    1. Della-Torre E, Campochiaro C, Cavalli G, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. 2020;79:1277–1285. - PMC - PubMed
    1. Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21:382–393. - PMC - PubMed
    1. U.S. Food and Drug Administration Coronavirus (COVID-19) update: FDA authorizes drug for treatment of COVID-19. 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19...

LinkOut - more resources